Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Treating patients with renal cell cancer in later lines of therapy

Viktor Grunwald • 3 Nov 2023
ESMO 2023
Genitourinary Cancer Kidney Cancer Belzutifan Cabozantinib Everolimus
MK-6482-005 MK-6482-011

Viktor Grünwald, MD, PhD, University Hospital Essen, Essen Germany, discusses the challenges in finding therapies for patients with renal cell cancer in later treatment lines. Dr Grünwald elaborates on trials that implicate belzutifan as a useful agent in this context, both as a monotherapy and in combination with other agents. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Viktor Grunwald

1:56
Updates in the treatment of genitourinary cancers
Viktor Grunwald • 25 Oct 2023
2:20
Open questions in urothelial carcinoma
Viktor Grunwald • 25 Oct 2023
2:03
Lesion responses to lenvatinib and pembrolizumab based on organ sites
Viktor Grunwald • 25 Oct 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals